• 1
    Lepor H, Nieder A, Feser J, O'Connell C, Dixon C. Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology 1997; 49: 47680
  • 2
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892900
  • 3
    Elhilali MM, Ramsey EW, Barkin J et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996; 47: 33542
  • 4
    Hampel C, Dolber PC, Smith MP et al. Modulation of bladder α1 adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002; 167: 151321
  • 5
    Schwinn DA. The role of α1 adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001; 88: 2734
  • 6
    Malloy BJ, Price DT, Price RR et al. α1 adrenergic receptor subtypes in human bladder. J Urol 1998; 160: 93743
  • 7
    Michel MC, Buscher R, Kerker J et al. α1-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 348: 38595
  • 8
    Testa R, Poggesi E, Taddei C, Guarnei L, Ibba M, Leonardi A. A new α1-antagonist selective for the lower urinary tract: in vitro studies. Neurourol Urodynam 1994a; 13: 4734
  • 9
    Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel α1 adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1 adrenoceptors. Jpn J Pharmacol 1999; 79: 44754
  • 10
    Welch G, Kawachi I, Barry MJ, Giovannucci E, Colditz GA, Willett WC. Distribution between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the health professionals follow-up study. Urology 1998; 51: 4227
  • 11
    Schwinn DA, Johnston GI, Page SO et al. Cloning and pharmacological characterization of human alpha-adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exper Ther 1995; 272: 13442
  • 12
    Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193202
  • 13
    Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct α1–adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 54651
  • 14
    Nasu K, Moriyama N, Kawabe K et al. Quantification and distribution of alpha 1-adrenergic subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non hypertrophied tissue. Br J Pharmacol 1996; 119: 797803
  • 15
    Kawabe K. Current status of research on prostate-selective alpha 1-antagonists. Br J Urol 1998; 81: 4850
  • 16
    Gregorini L, Marco J, Kozakova M et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99: 48290
  • 17
    Rudner XL, Berkowitz DE, Booth JV et al. Subtype specific regulation of human vascular alpha 1-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 233643
  • 18
    Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003; 170: 64953
  • 19
    Smith MS, Schambra UB, Wilson KH, Page SO, Schwinn DA. Alpha-1 adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha 1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 1999; 63: 25461
  • 20
    Persson K, Pandita RK, Spitsbergen J, Steers WD, Tuttle JB, Andersson KE. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275: R 1366–73
  • 21
    Das AK, Leggett RE, Whitbeck C, Eagen G, Levin RM. Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 2002; 21: 1606
  • 22
    Noble AJ, Chess-Williams R, Couldwell C et al. The effects of tamsulosin, a high affinity antagonist at functional α1A- and α1D-adrenoceptor subtypes. Br J Pharmacol 1997; 120: 2318
  • 23
    Nishino Y, Ogura T, Yamada T, Ishihawa S, Deguchi T. Assessment of two α1 adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, on voiding disturbance in benign prostatic hyperplasia, a randomized cross-over study. ICS Proceedings 2002: 116
  • 24
    Ikemoto I, Kiyota H, Ohishi Y et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol 2003; 10: 58794